Can an Anti-Inflammatory drug improve recovery from a rare stroke type?
NCT ID NCT07801638
First seen Sep 03, 2026 · Last updated Sep 10, 2026 · Updated 3 times
Summary
This trial tests whether adding tocilizumab, an anti-inflammatory drug, to standard blood thinners improves recovery in people with acute cerebral venous thrombosis, a type of stroke caused by a blood clot in the brain's veins. Researchers will give 80 adults either a single infusion of tocilizumab or a placebo, alongside standard treatment. They will measure disability, stroke severity, and headache impact over three months to see if the drug helps.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- tocilizumab, an anti-inflammatory drug, given as a single intravenous infusion alongside standard anticoagulation
- What this could lead to
- If it works, adding tocilizumab to standard care could reduce disability and speed recovery after cerebral venous thrombosis.
- What could go wrong
- This is an early-stage trial with 80 participants, so results may not apply broadly. Tocilizumab can increase infection risk and may not improve outcomes beyond standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2025
- Expected to finish
-
Sep 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Aged 18-80 years. 2. Acute cerebral venous thrombosis (CVT) confirmed by neuroimaging, including MRI, MRV, CTV, MRBTI, or DSA. 3. Time from symptom onset to enrollment within 14 ± 14 days. 4. Written informed consent obtained from the participant. 5. Ability and willingness to comply with the study protocol and scheduled follow-up visits. Exclusion Criteria: 1. Treatment with immunosuppressive agents within 7 days before enrollment. 2. Isolated cortical vein thrombosis or isolated cavernous sinus thrombosis. 3. Concomitant immune-related diseases, including Behçet disease or systemic lupus erythematosus. 4. Concomitant infectious diseases. 5. Primary or secondary immunodeficiency. 6. Concomitant hematologic disorders or inherited coagulation abnormalities. 7. Intracerebral hemorrhage with extension into the ventricular system or subarachnoid space. 8. Imaging evidence of midline shift \>10 mm or cerebral herniation. Moderate or severe hepatic impairment, defined as Child-Pugh class B or C. 9. Creatinine clearance \<30 mL/min. 10. Severe trauma or major surgery within 2 weeks before enrollment. 11. Serious comorbid disease that may result in an unfavorable prognosis within 1 year. 12. Pregnancy, puerperium, or breastfeeding. 13. Contraindication to anti-IL-6 therapy. 14. Contraindication to anticoagulant therapy. 15. Psychiatric illness or inability to cooperate with study-related examinations or treatment. 16. Known allergy to contrast agents or study medication.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cerebral venous thrombosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Xuanwu Hospital
RECRUITINGBeijing, Beijing Municipality, 100053, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- French biobank aims to unlock secrets of rare brain vessel diseases
- 3000 patients join study to unravel brain clot mystery
- Blood tests may help predict recovery in rare brain clot condition
- Brain vein study tests new MRI to see lymph nodes
- Snake venom enzyme could boost stroke recovery in rare brain clot study
- Eye ultrasound could replace needles for measuring brain pressure in kids